Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Determination of Related Protease Inhibition from US Patent US20240059691: "ENZYME INHIBITORS"
Assay data:279 Active, 16 Activity ≤ 1 nM, 253 Activity ≤ 1 µM, 299 Tested
SummaryRelated BioAssays by Target
Binding affinity to human FXIa assessed as induction of higher order oligomers formation at 100 uM by analytical ultracentrifugation study analysis
Assay data:1 Tested
Binding affinity to covalently inhibited human FXIa-PMSF assessed as induction of higher order oligomers formation at 100 uM by native PAGE analysis
Binding affinity to human FXIa assessed as induction of higher order oligomers formation at 100 uM by native PAGE analysis
Binding affinity to active site dansylated human DEGR-FXIa assessed as change in fluorescence intensity by fluorescence based analysis
Assay data:2 Tested
Binding affinity to active site dansylated human DEGR-FXIa assessed as maximal change in fluorescence intensity by fluorescence based analysis
Allosteric co-operative binding affinity to active site dansylated human DEGR-FXIa assessed as sigmoidal interaction by measuring change in fluorescence intensity by fluorescence based analysis
Assay data:1 Active, 1 Tested
Binding affinity to active site dansylated human DEGR-FXIa assessed as hyperbolic interaction by measuring change in fluorescence intensity by fluorescence based analysis
Non-competitive inhibition of human FXIa assessed as decrease in substrate Vmax with constant Km using S-2366 as chromogenic substrate by Michaelis-Menten based kinetics analysis
Inhibition of human FXIa using S-2366 as chromogenic substrate preincubated with enzyme for 10 mins followed by substrate addition by spectrophotometric analysis relative to control
Assay data:27 Tested
Inhibition of human FXIa using S-2366 as chromogenic substrate preincubated with enzyme for 10 mins followed by substrate addition by spectrophotometric analysis
Assay data:1 Active, 28 Tested
Inhibition of human fXIa incubated for 1 hrs
Inhibition of human fXIa using Boc-FSR-AMC as substrate assessed as inhibition constant by fluorescence plate reader analysis
Assay data:3 Tested
Inhibition of human fXIa using Z-Gly-Pro-Arg-AFC as substrate
Inhibition of human fXIa
Inhibition of fXIa (unknown origin)
Assay data:1 Active, 1 Activity ≤ 1 µM, 2 Tested
Biochemical Assay from US Patent US11884660: "Substituted oxopyridine derivative"
SummaryRelated BioAssays by DepositorRelated BioAssays by Target
Enzymatic Activity Assay from US Patent US20230391761: "SUBSTITUTED S-ALANINATE DERIVATIVES"
Assay data:17 Active, 14 Activity ≤ 1 nM, 17 Activity ≤ 1 µM, 17 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Factor XIa Inhibition Assay Utilizing a Fluorophore-Quencher Pair Peptide Substrate from US Patent US20230295157: "3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS"
Assay data:341 Active, 112 Activity ≤ 1 nM, 356 Activity ≤ 1 µM, 357 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Factor XIa Assay from US Patent US20230286958: "PLASMA KALLIKREIN INHIBITORS"
Assay data:136 Active, 63 Activity ≤ 1 µM, 185 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on